Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis

BACKGROUND: Biologic disease-modifying antirheumatic drug (DMARD) therapies are a mainstay of treatment for rheumatoid arthritis (RA), yet high member out-of-pocket (OOP) costs for such therapies may limit patient access to these therapies. OBJECTIVE: To understand whether there is a relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopson, Sari, Saverno, Kim, Liu, Larry Z., AL-Sabbagh, Ahmad, Orazem, John, Costantino, Mary E., Pasquale, Margaret K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397931/
https://www.ncbi.nlm.nih.gov/pubmed/27015251
http://dx.doi.org/10.18553/jmcp.2016.14261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397931/
https://www.ncbi.nlm.nih.gov/pubmed/27015251
http://dx.doi.org/10.18553/jmcp.2016.14261

Ejemplares similares